Turn Therapeutics Soars 26% After Positive Alzheimer’s Data and Phase II Expansion
TTRX•Turn Therapeutics reported positive Alzheimer’s data, sparking a 26.3% rally in its shares and prompting expansion of its Phase II trial to broader patient cohorts. Industry research estimates the AD market will grow from $8.5bn in 2023 to $22.4bn by 2033, underscoring significant commercial upside.
1. Interim AD Biomarker Results
In its Phase II Alzheimer’s program, Turn Therapeutics achieved favorable shifts in key biomarkers, demonstrating target engagement and an acceptable safety profile in early-stage patients.
2. Phase II Trial Expansion
Following the positive interim analysis, the company broadened enrollment criteria and added additional patient cohorts and an open-label extension to accelerate data collection.
3. Market Opportunity Projection
Industry research projects the global AD therapeutic market expanding from $8.5bn in 2023 to $22.4bn by 2033 across major regions, highlighting significant growth potential.
4. Stock Price Reaction
Shares of Turn Therapeutics surged 26.27% on the news, reflecting heightened investor confidence and adjusted valuation assumptions for its Alzheimer’s pipeline.
